Prior studies have shown that elevated CTSZ expression is significantly associated with unfavorable clinical outcomes in multiple malignancies, including renal cell carcinoma, colorectal cancer, and esophageal cancer (40–42). Here, CTSZ is linked to esophageal cancer.